22.01.2024 19:35:53

EQS-News: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG

EQS-News: The Rosen Law Firm P. A. / Key word(s): Financial
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG

22.01.2024 / 19:35 CET/CEST
The issuer is solely responsible for the content of this announcement.


WHY: NEW YORK, NY - 65aeaaccda846f373deaca7f.gif(NewMediaWire) - January 22, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of MiMedx Group, Inc. (NASDAQ: MDXG) resulting from allegations that MiMedx may have issued materially misleading business information to the investing public.

65aeaaccda846f373deaca7f_1SO WHAT: If you purchased MiMedx’s securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21901 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On December 29, 2023, MiMedx issued a press release announcing that “[f]ollowing a routine inspection earlier in the year, the United States Food and Drug Administration (“FDA”) took the position that one of the Company’s recently-launched placental-derived tissue products – AXIOFILL – does not meet the requirements as a Section 361 product and is therefore subject to enforcement as a Section 351 product. Specifically, FDA asserts that the production of AXIOFILL involves more than “minimal manipulation.” The Company does not agree with FDA’s position and has been actively engaged with the agency through its “Request For Designation” (“RFD”) process. However, on December 21, 2023, MIMEDX received a Warning Letter from FDA reiterating the agency’s position on AXIOFILL.”

On this news, MiMedx’s stock price fell $0.90 per share, or 10.26%, to close at $7.87 per share on January 2, 2024.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.
      
Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      cases@rosenlegal.com
      www.rosenlegal.com


News Source: NewMediaWire


22.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: The Rosen Law Firm P. A.
United States
ISIN: US6024961012
EQS News ID: 1820427

 
End of News EQS News Service

1820427  22.01.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1820427&application_name=news&site_id=smarthouse

Analysen zu MiMedx Group Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

MiMedx Group Inc 9,39 2,85% MiMedx Group Inc